Breaking News Instant updates and real-time market news.

SESN

Sesen Bio

$1.46

-0.39 (-21.08%)

, NEPT

Neptune Wellness

$4.40

-0.14 (-3.08%)

08:45
06/20/19
06/20
08:45
06/20/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sesen Bio (SESN) 71.48% +22.34, Neptune Technologies (NEPT) 19.08% +0.25, Cenovus Energy (CVE) 0.50% +0.23, Viking Therapeutics (VKTX) 2.97% +0.14, db X trackers China (ASHR) 3.23% +0.09, Realogy (RLGY) 0.81% +0.07, Anaplan (PLAN) 0.42% +0.06, Chevron (CVX) 0.37% +0.05, Tencent (TME) 4.52% +0.03, and ProShares UltraPro QQQ (TQQQ) 1.58% +0.03.

SESN

Sesen Bio

$1.46

-0.39 (-21.08%)

NEPT

Neptune Wellness

$4.40

-0.14 (-3.08%)

CVE

Cenovus Energy

$8.76

-0.12 (-1.35%)

VKTX

Viking Therapeutics

$8.22

-0.13 (-1.56%)

ASHR

X-trackers Harvest CSI 300

$27.32

0.01 (0.04%)

RLGY

Realogy

$7.34

0.05 (0.69%)

PLAN

Anaplan

$51.05

0.355 (0.70%)

CVX

Chevron

$122.94

-0.01 (-0.01%)

TME

Tencent Music

$15.03

-0.08 (-0.53%)

TQQQ

ProShares UltraPro QQQ

$61.93

0.7 (1.14%)

  • 25

    Jun

  • 26

    Jun

  • 25

    Jul

  • 19

    Jun

SESN Sesen Bio
$1.46

-0.39 (-21.08%)

06/11/19
HCWC
06/11/19
UPGRADE
Target $3
HCWC
Buy
Sesen Bio upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth upgraded Sesen Bio to Buy from Neutral and raised his price target for the shares to $3.00 from $1.00. The company yesterday announced that it has successfully completed a Type B pre-Biologics License Application meeting with FDA for lead product, Vicinium, for the treatment of patients with Bacillus Calmette-Guerin unresponsive, non-muscle invasive bladder cancer, Ramakanth tells investors in a research note. Following this "green light" from the FDA, the analyst believes there is a high likelihood that Vicinium will be approved. He now projects a 90% probability of U.S. approval, up from 60% previously.
02/06/19
JEFF
02/06/19
INITIATION
Target $3
JEFF
Buy
Sesen Bio assumed with a Buy at Jefferies
Jefferies analyst Chris Howerton assumed coverage of Sesen Bio with a Buy rating and $3 price target. The analyst believes the company's Vicinium will be approvable in 2020 or 2021 with peak U.S. sales potential of $260M in 2034.
01/04/19
HCWC
01/04/19
DOWNGRADE
Target $1
HCWC
Neutral
Sesen Bio downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Sesen Bio to Neutral and lowered his price target for the shares to $1 from $3. While the Phase 3 Vista results "appear decent in isolation," the failure to improve on the Phase 2 results despite a more rigorous treatment schedule introduces additional uncertainties on the regulatory and commercial prospects of Vicinium, Ramakanth tells investors in a research note. The full Vista results are not expected until mid-2019, which could potentially render the stock range-bound until then, says the analyst.
07/23/18
JEFF
07/23/18
INITIATION
Target $4
JEFF
Buy
Sesen Bio initiated with a Buy at Jefferies
Jefferies analyst Matthew Andrews started Sesen Bio with a Buy rating and $4 price target. The analyst sees share upside through 2019 driven by 12-month complete response data and FDA agreeing to accelerated approval for Vicinium.
NEPT Neptune Wellness
$4.40

-0.14 (-3.08%)

04/09/19
MITR
04/09/19
INITIATION
MITR
Buy
Neptune Wellness initiated with a Buy at GMP Securities
GMP Securities initiated Neptune Wellness with a Buy rating and C$7 price target.
CVE Cenovus Energy
$8.76

-0.12 (-1.35%)

04/23/19
SBSH
04/23/19
NO CHANGE
SBSH
Neutral
Citi opens '30-Day Upside Catalyst Watch' on Cenovus Energy
Citi analyst Prashant Rao opened a "30-Day Upside Catalyst Watch" on Neutral-rated Cenovus Energy. Stronger price realizations in the upstream due to higher benchmark oil prices and narrowed Canadian differentials could drive "meaningful upside" to Wednesday's Q1 results, Rao tells investors in a research note. The analyst also sees the potential for upward Q2 estimate revisions, helped by "bullish sentiment" for continued upstream price strength in the near-to-intermediate term.
04/16/19
04/16/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Netflix (NFLX) upgraded to Buy from Hold at Deutsche Bank with analyst Bryan Kraft saying consensus subscriber expectations for both 2019 and 2020 now seem conservative. 2. Cenovus Energy (CVE) upgraded to Neutral from Sell at Goldman Sachs with analyst Neil Mehta citing improvements to the company's leverage outlook and a more constructive commodity price environment, particularly for Canadian heavy crude. 3. Cummins (CMI) upgraded to Buy from Neutral at Citi with analyst Timothy Thein saying he sees upside to 2019 estimates and thinks the company's out-year cash flows "stay higher for longer based on end market diversity and increasing contribution from the aftermarket." 4. Western Digital (WDC) upgraded to Buy from Hold at Deutsche Bank with analyst Sidney Ho starting to see favorable data points in both hard disk drive and NAND that will support a "solid" second half of the year recovery for Western Digital's earnings. 5. e.l.f. Beauty (ELF) upgraded to Buy from Neutral at DA Davidson with analyst Linda Bolton Weiser citing the findings of her proprietary store checks suggesting that the company products have seen a 17% increase in shelf space at Target (TGT), overtaking Coty's (COTY) Covergirl brand, while its Q1 sales "inflected from down high-single digits" in Q4 to low-single digits. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/16/19
GSCO
04/16/19
UPGRADE
Target $11
GSCO
Neutral
Cenovus Energy upgraded to Neutral with $11 price target at Goldman Sachs
Goldman Sachs analyst Neil Mehta upgraded Cenovus Energy (CVE) to Neutral from Sell and raised his price target for the shares to $11 from $7.50. The analyst cites improvements to the company's leverage outlook and a more constructive commodity price environment, particularly for Canadian heavy crude, for the upgrade. However, he stills see more upside to Buy-rated ConocoPhillips (COP), Canadian Natural Resources (CNQ), Suncor (SU) and Imperial Oil (IMO) among large cap North American oils than Cenovus.
04/16/19
GSCO
04/16/19
UPGRADE
GSCO
Neutral
Cenovus Energy upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Neil Mehta upgraded Cenovus Energy to Neutral from Sell.
VKTX Viking Therapeutics
$8.22

-0.13 (-1.56%)

03/29/19
LEER
03/29/19
UPGRADE
LEER
Outperform
Viking Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
04/11/19
HCWC
04/11/19
NO CHANGE
Target $31
HCWC
Buy
Viking Therapeutics data 'compelling' at low doses, says H.C. Wainwright
Viking Therapeutics reported additional results this morning from its 12-week Phase 2 data of the lower 5mg dose of VK2809 in patients with non-alcoholic fatty liver disease. The "compelling" results show "impressive" safety and efficacy at low doses, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. Importantly, VK2809 at low doses is able to "significantly reduce" liver fat content in 12 weeks to an extent similar to the one demonstrated by the higher doses tested, says the analyst. He reiterates a Buy rating on Viking Therapeutics with a $31 price target.
04/18/19
HCWC
04/18/19
NO CHANGE
Target $31
HCWC
Buy
Viking bear thesis based on 'fears and alternative facts,' says H.C. Wainwright
Bear pressure on Viking Therapeutics is "winning by share performance metric," but it is based on "fears and alternative facts," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. He believes Viking's shares are not reflecting the "compelling data" delivered to date for VK2809, as well as VK5211. The "massive" short interest, currently about 45% of shares outstanding, has been putting "significant pressure on the shares following highly positive news events," says Pantginis. The analyst continues to believe VK2809 represents a potential best-in-class molecule that could "also benefit from the clear definition of regulatory paths and questions established by others." He reiterates a Buy rating on Viking Therapeutics with a $31 price target.
05/15/19
WBLR
05/15/19
NO CHANGE
WBLR
Outperform
Viking Therapeutics risk/reward symmetry skewed to upside, says William Blair
William Blair analyst Andy Hsieh reiterates an Outperform rating on Viking Therapeutics (VKTX) after hosting investor meetings the company's CEO Brian Lian. The analyst continues to view Viking's risk/reward symmetry as skewed to the upside, especially with the recent sector volatility and the "continued significant valuation gap" with competitor Madrigal Pharmaceuticals (MDGL). Viking is on track to file an investigational new drug application later this year to the FDA's Division of Gastroenterology and Inborn Errors Products, which would enable the company to initiate the Phase II biopsy-confirmed nonalcoholic steatohepatitis study, Hsieh tells investors in a research note.
ASHR X-trackers Harvest CSI 300
$27.32

0.01 (0.04%)

RLGY Realogy
$7.34

0.05 (0.69%)

06/10/19
SPHN
06/10/19
UPGRADE
Target $23
SPHN
Overweight
Redfin upgraded to Overweight from Underweight at Stephens
Stephens analyst John Campbell double upgraded Redfin (RDFN) to Overweight from Underweight and raised his price target for the shares to $23 from $18. The analyst this morning also downgraded Realogy Holdings (RLGY) to Equal Weight from Overweight. The recent pullback in Redfin shares has brought a "very favorable" near-term setup as the company lays the groundwork for a more e-commerce type offering, Campbell tells investors in a research note. Many of the company's top markets are in the process of recovering from a tough in the second half of 2018, adds the analyst. As a result, he sees improved operating results moving forward.
06/10/19
06/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cheniere Energy Partners (CQP) downgraded to Sector Perform from Outperform at RBC Capital with analyst Elvira Scotto saying while she views the company's positive FID on Train 6 and updated run-rate guidance positively, she believes these announcements were in line with expectations. 2. At Home Group (HOME) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Simeon Gutman saying after the company's recent earnings miss and guidance cut that its headwinds appear less transitory than he'd previously thought. 3. Lazard (LAZ) downgraded to Neutral from Buy at UBS with analyst Brennan Hawken saying the company's pipeline of advisory revenue has been "weak." 4. Insulet (PODD) downgraded to Market Perform from Outperform at Northland with analyst Suraj Kalia citing valuation. 5. Realogy (RLGY) downgraded to Equal Weight from Overweight at Stephens with analyst John Campbell saying he believes the company will sees a "depressed multiple" until it can prove the sustainability of its model, which he thinks will take at least a few quarters of consistent earnings growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/10/19
SPHN
06/10/19
DOWNGRADE
Target $8
SPHN
Equal Weight
Realogy downgraded to Equal Weight from Overweight at Stephens
Stephens analyst John Campbell downgraded Realogy Holdings to Equal Weight from Overweight and cut his price target for the shares to $8 from $16. The analyst believes the company will sees a "depressed multiple" until it can prove the sustainability of its model, which he thinks will take at least a few quarters of consistent earnings growth. Further, Realogy's "hands are somewhat tied" given its debt position, which makes strategy development incrementally more challenging, Campbell tells investors in a research note.
05/03/19
COMP
05/03/19
DOWNGRADE
COMP
Sell
Realogy downgraded to Sell from Neutral at Compass Point
PLAN Anaplan
$51.05

0.355 (0.70%)

05/29/19
NEED
05/29/19
NO CHANGE
Target $54
NEED
Buy
Anaplan price target raised to $54 from $42 at Needham
Needham analyst Scott Berg raised his price target on Anaplan to $54 and kept his Buy rating after the company "crushed" on its Q1 results with accelerating billings growth and raised its FY20 guidance. The analyst notes that the quarter was highlighted by a "fairly significant" boost in operating leverage thanks to Anaplan's increasing sales productivity as the company landed bigger initial deals with 60% higher average selling prices. Berg adds that the company's "breadth of use cases" is unrivaled and expects its market share gains to accelerate in the next several years.
05/29/19
RHCO
05/29/19
NO CHANGE
Target $52
RHCO
Buy
Anaplan price target raised to $52 from $45 at SunTrust
SunTrust analyst Terry Tillman raised his price target on Anaplan to $52 and kept his Buy rating after its Q1 results that showed accelerating revenue and billings growth. The analyst notes that the company's subscription and service revenue growth topped expectations, while the "scaling" of its revenue improved its operating cash flows. Tillman also raises Anaplan's FY19 and FY20 EPS forecasts by 9c and 4c to (60c) and (45c) respectively.
06/07/19
KEYB
06/07/19
UPGRADE
Target $57
KEYB
Overweight
Anaplan upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Brent Bracelin upgraded Anaplan to Overweight from Sector Weight with a $57 price target.
06/07/19
KEYB
06/07/19
UPGRADE
Target $57
KEYB
Overweight
Anaplan upgraded at KeyBanc on increasing confidence in growth drivers
KeyBanc analyst Brent Bracelin upgraded Anaplan to Overweight from Sector Weight with a $57 price target, citing increasing confidence in the upside levers to revenue following three quarters of accelerating billings growth, consistent subscription growth over the past year, and proprietary jobs data that shows strong hiring trends at Deloitte that could help elevate Anaplan as a key enabler of broader digital transformation initiatives.
CVX Chevron
$122.94

-0.01 (-0.01%)

05/13/19
SBSH
05/13/19
INITIATION
Target $135
SBSH
Buy
Chevron resumed with a Buy at Citi
Citi analyst Alastair Syme resumed coverage of Chevron with a Buy rating while lowering his price target for the shares to $135 from $142. The company's combination of yield and growth, underpinned by a competitive resource base, looks like an "attractive portfolio holding within global energy," Syme tells investors in a research note.
05/15/19
GSCO
05/15/19
UPGRADE
Target $144
GSCO
Conviction Buy
Chevron upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Neil Mehta reinstated a rating on Chevron (CVX) at Buy and added the stock to the firm's Americas Conviction List, stating that Chevron's cash flow profile has positively inflected with the production contribution and capital spending roll-off from the startup of both the Gorgon and Wheatstone LNG projects. Chevron is demonstrating capital discipline, as demonstrated by its decision not to make a counterproposal to Occidental Petroleum's (OXY) offer for Anadarko (APC), and it has a lower capital spending growth rate and a higher production growth rate through 2023 than its closest peer, Exxon (XOM), said Mehta. The analyst has a $144 price target on Chevron shares.
05/15/19
05/15/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Westlake Chemical (WLK) upgraded to Buy from Neutral at Goldman Sachs with analyst Robert Koort saying the stock's 49% decline over the past year has created an opportunity to gain exposure to two commodity cycles that are bottoming, ethylene and chloralkali. 2. Zillow (ZG, Z) upgraded to Buy from Neutral at Guggenheim with analyst Jake Fuller saying its recent results prove that demand for Offers "is real" and he expects the company's Offers business to surpass its ad business by Q4 and generate greater than $1B of revenue in its first full year. 3. Chevron (CVX) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Neil Mehta saying Chevron's cash flow profile has positively inflected with the production contribution and capital spending roll-off from the startup of both the Gorgon and Wheatstone LNG projects. 4. Hess Corp. (HES) upgraded to Equalweight from Underweight at Capital One with analyst Phillips Johnston saying he reviewed his model post Q1 earnings and "massively" overhauled his Guyana production estimates. 5. Applied Materials (AMAT) and Advanced Energy (AEIS) upgraded to Positive from Neutral at Susquehanna. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/16/19
ARGS
05/16/19
DOWNGRADE
ARGS
Hold
Occidental Petroleum downgraded to Hold from Buy at Argus
Argus analyst Bill Selesky downgraded Occidental Petroleum (OXY) to Hold after its confirmed purchase of Anadarko Petroleum (APC) for $76 per share, saying the company is overpaying for the assets with a bid well above that of Chevron's (CVX) $65 per share offer. The analyst believes that Occidental will "have difficulty" achieving the forecasted $3.5B cost synergies from the transactions. Selesky also contends that Anadarko's LNG and offshore assets are not a good strategic fir for Occidental, adding that its valuation multiple near the low end of 52-week range is "warranted."
TME Tencent Music
$15.03

-0.08 (-0.53%)

03/20/19
FBCO
03/20/19
DOWNGRADE
FBCO
Neutral
Tencent Music downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse downgraded Tencent Music to Neutral from Outperform citing valuation.
05/13/19
CHRS
05/13/19
INITIATION
CHRS
Hold
Tencent Music initiated with a Hold at China Renaissance
06/04/19
LOOP
06/04/19
INITIATION
Target $19
LOOP
Buy
Tencent Music initiated with a Buy at Loop Capital
As previously reported, Loop Capital analyst Rob Sanderson initiated Tencent Music with a Buy rating and a price target of $19. The analyst is positive on the company blending its music product and social entertainment, with the revenue growth of the latter driven by "livestreaming and online karaoke" products. Sanderson adds that Tencent Music's monetization from virtual gifting and margins are higher than that of other music distributors, and he sees a large opportunity to expand the company's paid user participation in social activities on the platform that will also lead to accelerating growth in its premium music subscriptions.
06/13/19
CICC
06/13/19
INITIATION
CICC
Buy
Tencent Music initiated with a Buy at CICC
TQQQ ProShares UltraPro QQQ
$61.93

0.7 (1.14%)

TODAY'S FREE FLY STORIES

AZRE

Azure Power

$10.61

0.16 (1.53%)

16:35
07/17/19
07/17
16:35
07/17/19
16:35
Hot Stocks
Azure Power names Ranjit Gupta as new CEO »

Azure Power announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEGH

Legacy Housing

$12.79

-0.01 (-0.08%)

16:35
07/17/19
07/17
16:35
07/17/19
16:35
Hot Stocks
Legacy Housing appoints Cornelius Van Den Handel CFO »

Legacy Housing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REI

Ring Energy

$3.05

-0.085 (-2.72%)

16:33
07/17/19
07/17
16:33
07/17/19
16:33
Hot Stocks
Ring Energy provides Q2 operations update »

Ring Energy released its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:33
07/17/19
07/17
16:33
07/17/19
16:33
Conference/Events
Federal Reserve Bank of New York president delivers keynote address »

New York Federal Reserve…

ECOL

US Ecology

$61.95

1.14 (1.87%)

, NRCG

NRC Group

$11.81

0.03 (0.25%)

16:33
07/17/19
07/17
16:33
07/17/19
16:33
Hot Stocks
US Ecology, NRC Group granted early termination of HSR waiting period »

The Federal Trade…

ECOL

US Ecology

$61.95

1.14 (1.87%)

NRCG

NRC Group

$11.81

0.03 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

CATY

Cathay General

$34.76

-0.04 (-0.11%)

16:32
07/17/19
07/17
16:32
07/17/19
16:32
Earnings
Cathay General reports Q2 EPS 90c, consensus 87c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

16:32
07/17/19
07/17
16:32
07/17/19
16:32
Conference/Events
The Brookings Institution to hold a conference on the US-China Trade War »

The Global Economy &…

BXS

BancorpSouth

$28.14

-0.38 (-1.33%)

16:31
07/17/19
07/17
16:31
07/17/19
16:31
Earnings
BancorpSouth reports Q2 operating EPS 61c, consensus 61c »

"We are pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

YEXT

Yext

$21.06

0.49 (2.38%)

16:31
07/17/19
07/17
16:31
07/17/19
16:31
Conference/Events
Olive Tree to hold a panel discussion »

Olive Tree Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

16:30
07/17/19
07/17
16:30
07/17/19
16:30
Options
Preliminary option volume of 18.3M today »

Preliminary option volume…

16:29
07/17/19
07/17
16:29
07/17/19
16:29
Conference/Events
Piper Jaffray to hold a conference »

BioInsights KOL Series…

TBK

Triumph Bancorp

$27.45

-0.27 (-0.97%)

16:29
07/17/19
07/17
16:29
07/17/19
16:29
Hot Stocks
Triumph Bancorp announces additional $25M to repurchase authorization »

On July 17, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 23

    Sep

GPC

Genuine Parts

$102.27

-3.07 (-2.91%)

16:27
07/17/19
07/17
16:27
07/17/19
16:27
Hot Stocks
Genuine Parts to acquire Todd Group, terms not stated »

Genuine Parts announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

TBK

Triumph Bancorp

$27.45

-0.27 (-0.97%)

16:27
07/17/19
07/17
16:27
07/17/19
16:27
Earnings
Triumph Bancorp reports Q2 EPS 48c, consensus 48c »

The company earned net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Aug

  • 23

    Sep

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:25
07/17/19
07/17
16:25
07/17/19
16:25
Hot Stocks
Breaking Hot Stocks news story on eBay »

eBay up 5% to $40.95…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

CNS

Cohen & Steers

$51.92

-0.415 (-0.79%)

16:25
07/17/19
07/17
16:25
07/17/19
16:25
Earnings
Cohen & Steers reports Q2 adjusted EPS 62c, consensus 63c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CNS

Cohen & Steers

$51.92

-0.415 (-0.79%)

16:23
07/17/19
07/17
16:23
07/17/19
16:23
Earnings
Cohen & Steers reports Q2 EPS 62c, consensus 63c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:22
07/17/19
07/17
16:22
07/17/19
16:22
Hot Stocks
eBay reaches commercial agreement with Paytm Mall »

eBay has taken two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:21
07/17/19
07/17
16:21
07/17/19
16:21
Hot Stocks
eBay achieves over $270M of GMV during Q2 »

eBay accelerated adoption…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

EBAY

eBay

$39.03

-0.87 (-2.18%)

16:20
07/17/19
07/17
16:20
07/17/19
16:20
Hot Stocks
eBay grew active buyers by 4% across its platforms in Q2 »

In the second quarter,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/17/19
07/17
16:20
07/17/19
16:20
Options
Closing CBOE SPX and VIX Index summary for July 17th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYY

Sysco

$71.75

-0.865 (-1.19%)

16:19
07/17/19
07/17
16:19
07/17/19
16:19
Initiation
Sysco initiated at Consumer Edge »

Sysco initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

  • 25

    Sep

CCI

Crown Castle

$131.60

-1.08 (-0.81%)

16:19
07/17/19
07/17
16:19
07/17/19
16:19
Earnings
Crown Castle reports Q2 EPS 52c, consensus 41c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

TSC

TriState Capital

$19.71

-0.31 (-1.55%)

16:19
07/17/19
07/17
16:19
07/17/19
16:19
Earnings
TriState Capital reports Q2 EPS 47c, consensus 45c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 23

    Sep

PLXS

Plexus

$59.86

-1.6 (-2.60%)

16:19
07/17/19
07/17
16:19
07/17/19
16:19
Earnings
Plexus sees Q4 EPS 81c-91c, consensus 96c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.